The complaint filed against the NASDAQ-listed firm centers on claims that management violated the Securities Exchange Act of 1934. Specifically, the lawsuit contends that Immutep filed an SEC Form-K on January 30, 2026, characterizing the TACTI-004 trial of its candidate drug, efti, as showing strong operational progress. Plaintiffs argue that this description was materially misleading, as the company allegedly possessed information indicating the trial was failing to achieve its required efficacy benchmarks.
Immutep Faces Securities Class Action Over Alleged Trial Misrepresentations
Investors who purchased Immutep Limited stock between March 24, 2025, and March 12, 2026, are being urged to join a class action lawsuit. The litigation alleges the company misled the market regarding the efficacy of its eftilagimod alfa clinical trial, despite internal knowledge that primary endpoints would not be met.
The DJS Law Group is currently soliciting contact from affected shareholders to discuss potential lead plaintiff appointments, noting that such a role is not a prerequisite for sharing in any eventual recovery. Interested parties have until July 6, 2026, to take action regarding the case. The firm specializes in securities litigation and corporate governance, representing a client base that includes major hedge funds and institutional asset managers.
Comments (0)
No comments yet. Be the first!